Axovant Sciences Ltd. (AXON) and Equillium Inc. (NASDAQ:EQ) Contrasting side by side

Since Axovant Sciences Ltd. (NASDAQ:AXON) and Equillium Inc. (NASDAQ:EQ) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of both companies.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Axovant Sciences Ltd. N/A 0.00 145.34M -1.53 0.00
Equillium Inc. N/A 0.00 9.82M -0.71 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 provides us the net margins, return on equity and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Axovant Sciences Ltd. 0.00% -302.2% -119.2%
Equillium Inc. 0.00% 0% 0%


2 and 2 are the respective Current Ratio and a Quick Ratio of Axovant Sciences Ltd. Its rival Equillium Inc.’s Current and Quick Ratios are 1.9 and 1.9 respectively. Axovant Sciences Ltd. has a better chance of clearing its pay short and long-term debts than Equillium Inc.

Insider & Institutional Ownership

Roughly 9.2% of Axovant Sciences Ltd. shares are held by institutional investors while 0.99% of Equillium Inc. are owned by institutional investors. Axovant Sciences Ltd.’s share held by insiders are 61.44%. Comparatively, Equillium Inc. has 21.3% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Axovant Sciences Ltd. -31.49% -39.51% -40.95% -75.25% -75.3% -76.47%
Equillium Inc. -14.15% -17.66% 0% 0% 0% 0.57%

For the past year Axovant Sciences Ltd. had bearish trend while Equillium Inc. had bullish trend.


On 5 of the 6 factors Equillium Inc. beats Axovant Sciences Ltd.

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of AlzheimerÂ’s disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD. In addition, it focuses on developing RVT-103, a combination of donepezil and a peripheral muscarinic receptor antagonist; and RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1 clinical trials for the treatment of acute graft-versus-host disease and asthma. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.